
Suliman Al-Fayoumi
Senior Advisor, Global Pharma Strategy & FDA Compliance
+1 206 413 5122
English
Dr. Al-Fayoumi is currently a Principal Clinical Pharmacology Consultant providing support to several biotech companies within the US, Europe and India.
Prior to pursuing consulting on a full-time basis, he served as Vice president, Clinical Pharmacology & PK/PD Modeling and Simulations, at Allucent supporting several small Biotech companies primarily based in USA. Before joining Allucent in 2021, Dr. Al-Fayoumi served as Vice President of Translational Sciences and Clinical Pharmacology at Cell Therapeutics Biopharma Inc., a hematology-oncology company based in Seattle, WA between 2013-2017. Moreover, Dr. Al-Fayoumi served as Director of Preclinical and Clinical Pharmacology and Interim Head of Research at Acucela Inc., an Ophthalmology company based in Seattle, WA between 2010 2013. Additionally, he served as Associate Director of Global PK/PD within the DMPK Department at Novartis Pharmaceuticals (East Hanover, NJ), where he supported the Cardiovascular & Metabolism (CVM) Franchise between 2006-2010. It is worth noting that Dr. Al-Fayoumi also served as Senior Clinical Pharmacology Reviewer at US FDA between 1999-2006 supporting GI, anticoagulants, anesthetics, addiction and dermatology Drug Product Divisions.
While at FDA, Dr. Al-Fayoumi was the primary clinical pharmacology reviewer for several high-profile drug applications such as Nexium, Prilosec OTC, Prevacid, Oxycontin, Ximelagatran, Asacol, Remicade, Lovenox, Innohep, Exjade, Propulsid, Etreva, Fabrazyme, Zegerid, Protonix, Lotronex and Zelnorm. Dr. Al-Fayoumi received several awards for outstanding support of and significant contributions to the achievement of excellence in FDA drug safety initiatives related to optimal dosing and lowest effective dose including CDER’s Frances O. Kelsey Drug Safety Excellence Award.
Qualifications
Regulatory Affairs and FDA Compliance
Hematology-Oncology and Therapeutics
Multinational Collaboration and Strategy